PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models

Abstract Background Enhancing the antitumor activity of the DNA-damaging drugs is an attractive strategy to improve current treatment options. Trabectedin is an isoquinoline alkylating agent with a peculiar mechanism of action. It binds to minor groove of DNA inducing single- and double-strand-break...

Full description

Bibliographic Details
Main Authors: Ymera Pignochino, Federica Capozzi, Lorenzo D’Ambrosio, Carmine Dell’Aglio, Marco Basiricò, Marta Canta, Annalisa Lorenzato, Francesca Vignolo Lutati, Sandra Aliberti, Erica Palesandro, Paola Boccone, Danilo Galizia, Sara Miano, Giulia Chiabotto, Lucia Napione, Loretta Gammaitoni, Dario Sangiolo, Maria Serena Benassi, Barbara Pasini, Giovanna Chiorino, Massimo Aglietta, Giovanni Grignani
Format: Article
Language:English
Published: BMC 2017-04-01
Series:Molecular Cancer
Subjects:
Predictive biomarkers
PARP1 inhibitors
DNA-damaging agents
Trabectedin
Olaparib
Bone and soft tissue sarcomas
Online Access:http://link.springer.com/article/10.1186/s12943-017-0652-5

Internet

http://link.springer.com/article/10.1186/s12943-017-0652-5

Similar Items